Main Article Content


Proton pump inhibitors (PPIs) are frequently used in patients who do not meet the criteria for appropriate use. Reducing inappropriate prescribing of PPIs in the inpatient and outpatient settings can minimize potential for adverse events, and can also help in controlling cost expenditure. The objective of the study is to determine the appropriateness and compare the cost of prescriptions of PPIs. A prospective observational study was conducted at a 750 bedded tertiary care teaching hospital in Coimbatore. The data were collected during regular ward rounds.  The appropriateness was analyzed using the FDA guidelines. A total of 209 patients was included in the study as per the inclusion criteria. In the study population pantoprazole was the most frequently prescribed in 144 (68.89%) patients, followed by esomeprazole in 46 (22.01%) patients, rabeprazole in 17 (8.13%) patients and omeprazole in 2 (0.95%) patients. Out of 209 patients 115 (55.02%) prescriptions were found to be appropriate and 94 (44.98%) prescriptions were found to be inappropriate as per the guidelines. The majority of the inappropriate prescriptions contained pantoprazole followed by esomeprazole and rabeprazole. The cost of treatment can be reduced in 94 patients who have been prescribed with PPIs inappropriately. The results revealed that interventions made by the pharmacist avoided the inappropriate use of PPI at the study site. Most of the inappropriate prescriptions were consisting increased frequency of dosing and utilizing PPIs for prophylactic use. The need for PPI use in the individual patient must be evaluated by the pharmacist and if any possible alternatives are found to be effective the same can be reported to the physician. The regular monitoring of prescription of PPI by clinical pharmacist is the need of the hour.


PPIs Appropriateness Cost comparison FDA guidelines

Article Details

How to Cite
Shivashankar Velu, & Pheba Susan Thomas. (2021). A study on appropriateness and cost comparison of prescription of proton pump inhibitors at a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 5(4), 286-290. Retrieved from


  1. [1]. Walker R and Whittlesea C. Clinical Pharmacy and Therapeutics. Churchill Livingstone Elsevier limited. 5th Edition 2012, 162-179.
  2. [2]. Proton Pump Inhibitors: Use in Adults. FDA. August 2013, 1-6.
  3. [3]. Chui D, Young F, Tejani A M, Dillon E C. Impact of academic detailing on proton pump inhibitor prescribing behavior in a community hospital. Canadian Pharmacists Journal. 144(2), 2011, 66-71.
  4. [4]. Salcedo J A, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med. 158 (8), 1998, 842-51.
  5. [5]. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID‐related gastrointestinal damage. Int J Clin Pract. 59(10), 2005, 1210-7.
  6. [6]. Heidelbaugh J J, Kim A H, Chang R, Walker P C. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther. Adv. Gastro enterol. 5(4), 2012, 219-32.
  7. [7]. Boardman H F, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Pharm. 37(5), 2015, 709-16.
  8. [8]. Mathew B, Mathew J, Kiran Y K. Study and assessment of appropriateness in the usage of proton pump inhibitors in a tertiary care teaching hospital in South India. Indo American Journal of Pharmaceutical Research. 5(9), 2015, 2849-56.
  9. [9]. Pottegard A, Broe A, Hallas J, de Muckadell O B, Lassen A T, Lodrup A B. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 26, 2016, 1-8.
  10. [10]. Jungnickel P W. Pantoprazole: a new proton pump inhibitor. Clin Ther. 22(11), 2000, 1268-93.
  11. [11]. Nirajan K, Kumaraswamy M, Surendra S, Saroj P, Bipin K, Thakur P, Jamuna T R. A study on proton pump inhibitors in general medicine unit of tertiary care teaching hospital. WJPR. 4(6), 2015, 1519-34.